Study examines public health impact of tamper resistant extended-release … -…

This is the first epidemiological study to examine the public health impact of a tamper resistant extended-release oxycodone (ORF). ER oxycodone was reformulated with physicochemical barriers to crushing and dissolving intended to reduce abuse through non-oral routes of administration. Manufacturer shipments of original ER oxycodone stopped on August 5, 2010, and ORF shipments started August 9, 2010. During the first 20 (more…)

Study finds reformulated ER Oxycodone abuse rates are significantly lower than … -…

  • Aims of this study were to assess 1) whether the rates of abuse of extended-release (ER) oxycodone (OxyContin®) decline following introduction of reformulated ER oxycodone (ORF), and 2) whether ORF is less likely to be abused through non-oral routes of administration that require tampering
  • Researchers obtained data from 140,496 individuals assessed for substance abuse treatment at 357 treatment centers
  • Findings were consistent with (more…)

Array BioPharma’s ARRY-797 Meets Primary Endpoint in Clinical Proof of … – MarketWatch (press release)

{}

BOULDER, Colo., Jul 31, 2012 (BUSINESS WIRE) — Array BioPharma /quotes/zigman/84685/quotes/nls/arry ARRY +1.78% today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs). Patients in all treatment groups continued using NSAIDs throughout (more…)